(2R-trans)-2,7-dihydro-2-methyl-3,7-diphenyl-5-propoxy-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2R-trans)-2,7-dihydro-2-methyl-3,7-diphenyl-5-propoxy-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine
• 英文别名: (2R,3R)-2-Methyl-3,7-diphenyl-5-propoxy-2,7-dihydro-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine；(4R,5R)-4-methyl-5,10-diphenyl-7-propoxy-3,6,8,10,11-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,7,11-tetraene
• 化学式: C₂₃H₂₃N₅O
• 分子量: 385.469
• InChiKey: SWJWVTBKVUVWHZ-UZLBHIALSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  左旋去甲麻黄碱 在 氯化亚砜 作用下， 以 丙醇 、 乙醇 、 乙腈 为溶剂， 反应 29.0h， 生成 (2R-trans)-2,7-dihydro-2-methyl-3,7-diphenyl-5-propoxy-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine
  参考文献：
  名称：

  Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors

  摘要：

  Two modes of tethering a chiral (phenylisopropyl)amino substituent in pyrazolo[3,4-d]pyrimidines and purines have been explored. One mode gave (S)-2,7-dihydro-7-phenyl-2-(phenylmethyl)-5-propoxy-3H-imidazo[1,2-c]pyrazolo-[4,3-e]pyrimidine (12a) and its corresponding R-enantiomer 12b, which were selective for A2 and A1 adenosine receptors, respectively. The corresponding diimidazo[1,2-c:4',5'-e]pyrimidines 12e and 12f were analogously selective. This is the first example where a single chiral recognition unit provides enantiomers with opposite selectivities for adenosine receptors. The second mode gave (2S-trans)-2,7-dihydro-2-methyl-3,7-diphenyl-5-propoxy-3H-imidazo[1,2-c]-pyrazolo[4,3-e]pyrimidine (12c) and its corresponding R-enantiomer 12d. Compounds 12c and 12d were significantly less potent than 12a and 12b at A1 receptors, and were nonselective.

  DOI：

  10.1021/jm00095a024

文献信息

• Selective adenosine reseptor compounds
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05064947A1

  公开（公告）日：1991-11-12

  Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which can be expected to enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.

  本文揭示了选择性作用于腺苷受体并且通常作为腺苷拮抗剂的腺苷类似物。从体外研究中已知，由于这种选择性，可以区分特定的生理效应，并且体外腺苷受体活性与体内腺苷受体活性相关。基于本文所述化合物的选择性结合活性，可以制备该化合物的药物制剂，预计可以增强某些生理效应，同时最小化其他效应，例如降低血压而不降低心率。
• Tricyclic fused adenine derivatives
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05086176A1

  公开（公告）日：1992-02-04

  Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which can be expected to enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.

  本文披露了选择性作用于腺苷受体并且通常作为腺苷拮抗剂的腺苷类似物。从体外研究中已知，由于这种选择性，可以区分特定的生理效应，并且体外腺苷受体活性与体内腺苷受体活性相关。基于本文中披露的化合物的选择性结合活性，可以制备主题化合物的制药制剂，可以预期增强某些生理效应，同时最小化其他效应，例如降低血压而不降低心率。
• Selective adenosine receptor compounds
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0390111A2

  公开（公告）日：1990-10-03

  Adenosine analogues of formule (I) which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which can be expected to enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate. wherein R₁ is hydrogen, phenyl or β-D-ribofuranosyl; R₂ is hydrogen, lower alkyl of from 1 to 4 carbon atoms or lower alkoxy of from 1 to 4 carbon atoms; Y is -N= or -CH=; Z is -N= or -CH=, with the proviso that Y and Z are not identical; n is an integer from 1 to 3, L is hydrogen or phenyl; and M is phenyl, except when L is phenyl, in which case M is hydrogen or a lower alkyl of from 1 to 3 carbon atoms.

  本研究公开了选择性作用于腺苷受体和一般作为腺苷拮抗剂的(I)式腺苷类似物。体外研究表明，由于这种选择性，可以区分特定的生理效应，并且体外腺苷受体活性与体内腺苷受体活性相关。根据本文公开的化合物的选择性结合活性，可以制备相关化合物的药物制剂，这些药物制剂可望增强某些生理效应，同时将其他效应降至最低，如降低血压而不降低心率。 其中 R₁ 是氢、苯基或 β-D-呋喃核糖基； R₂ 是氢、1 至 4 个碳原子的低级烷基或 1 至 4 个碳原子的低级烷氧基； Y 是-N= 或-CH=； Z 是-N= 或-CH=，但 Y 和 Z 不完全相同； n 是 1 至 3 的整数、 L 是氢或苯基 M 是苯基，除非 L 是苯基，在这种情况下，M 是氢或 1 至 3 个碳原子的低级烷基。
• US5064947A
  申请人：——

  公开号：US5064947A

  公开（公告）日：1991-11-12
• US5086176A
  申请人：——

  公开号：US5086176A

  公开（公告）日：1992-02-04